Table 1.
Patient characteristics
| Parameter | Chemotherapy only | Chemotherapy + lestaurtinib |
|---|---|---|
| Patients, n | 112 | 112 |
| Median age, y (range) | 54 (21-79) | 59 (20-81) |
| < 50 y, n | 34 | 33 |
| < 60 y, n | 79 | 64 |
| Male/female, n | 53/59 | 50/62 |
| FAB type, no. | ||
| M0 | 2 | 4 |
| M1 | 14 | 7 |
| M2 | 15 | 13 |
| M4 | 26 | 20 |
| M5 | 6 | 10 |
| M6 | 0 | 0 |
| M7 | 0 | 0 |
| Unknown | 49 | 58 |
| Duration of first CR, n (%) | ||
| 1-6 months | 53 (47) | 53 (47) |
| ≥ 6 months | 59 (53) | 59 (53) |
| FLT3 mutation, n | ||
| ITD only | 97 | 101 |
| D835 only | 8 | 9 |
| ITD and D835 | 6 | 2 |
| Not confirmed* | 1 | 0 |
FAB indicates French-American-British classification.
*
For a single patient, the FLT3 mutation status was not confirmed on central review.